# EDGAR Filing Document

**Accession Number:** 0001253497
**File Stem:** 0001253497-25-000010
**Filing Date:** 2025-12
**Character Count:** 7554
**Document Hash:** 0c3eaaa03020c642598db2213ee68f7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001253497-25-000010.hdr.sgml**: 20251210

**ACCESSION NUMBER**: 0001253497-25-000010

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251207

**FILED AS OF DATE**: 20251210

**DATE AS OF CHANGE**: 20251210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GLENN JOHN
- **CENTRAL INDEX KEY:** 0001253497

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36534
- **FILM NUMBER:** 251562619

**MAIL ADDRESS:**
- **STREET 1:** C/O IRADIMED CORPORATION
- **STREET 2:** 12705 INGENUITY DRIVE
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32826
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IRADIMED CORP
- **CENTRAL INDEX KEY:** 0001325618
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 731408526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 12705 INGENUITY DRIVE
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32826
- **BUSINESS PHONE:** 4076778022

**MAIL ADDRESS:**
- **STREET 1:** 12705 INGENUITY DRIVE
- **CITY:** ORLANDO
- **STATE:** FL
- **ZIP:** 32826

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GLENN JOHN<br><sub>(Last) (First) (Middle)</sub><br>C/O IRADIMED CORPORATION<br>12705 INGENUITY DRIVE<br><sub>(Street)</sub><br>ORLANDO, FL 32826<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CHIEF FINANCIAL OFFICER_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>IRADIMED CORP [ IRMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-07 |  | M |  | 10504<sup>(1)</sup> | A | <sup>(1)</sup> | 13004 | D |  |
| Common Stock | 2025-12-07 |  | F |  | 3383 | D | $94.57 | 9621 | D |  |
| Common Stock | 2025-12-07 |  | M |  | 21008<sup>(2)</sup> | A | <sup>(2)</sup> | 30629 | D |  |
| Common Stock | 2025-12-07 |  | F |  | 8267 | D | $94.57 | 22362 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | 2025-12-07 |  | M |  |  | 10504 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 10504 | $0 | 0 | D |  |
| Performance-based Restricted Stock Units | <sup>(2)</sup> | 2025-12-07 |  | M |  |  | 21008 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 21008 | $0 | 0 | D |  |

---

### Footnotes:

(1) Restricted stock units convert into common stock on a one-for-one basis.

(2) If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100%and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.

(3) The reporting person received restricted stock units ("RSUs") under Iradimed Corporation's 2014 Equity Incentive Plan.  The RSUs vest in full on the third anniversary of the grant date, December 7, 2025.  Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

(4) On December 7, 2022, the reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan.  Vesting of these PRSUs depends on the reporting person's achievement of specified relative ranking of total shareholder return over a three-year period from December 8, 2022 through December 7, 2025.

**Signature:** /s/ John Glenn  
**Date:** 2025-12-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**